Sector News

Baxter to sell biopharma unit to private equity for $4.25B

May 12, 2023
Life sciences

Baxter’s biopharma solutions business, which provides contract manufacturing and other support services for pharmaceutical companies, reported $644 million in revenue last year. It’s expected to generate roughly $600 million in revenue in 2023, the companies said in a statement.

Under Advent and Warburg’s ownership, it will operate as an independent contract development and manufacturing organization. The two private equity firms will acquire biopharma solutions’ manufacturing facilities, and roughly 1,700 employees in Indiana and Germany.

Advent Managing Partner John Maldonado said in a statement that the partnership can “unlock multiple opportunities for growth and help the business realize its full potential,” by serving large customers, including Baxter, with specialized, end-to-end capabilities as a standalone company.

CEO José Almeida said in an April earnings call that Baxter had seen “significant interest” in the biopharma solutions unit. READ MORE

by Elise Reuter

Source: biopharmadive.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach